✕

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Sell Alert: 10 Stocks Analysts Downgraded on Wednesday

Page 1 of 3

Wall Street got a sharp reminder this month of how fast sentiment can turn. Last Thursday the S&P 500 lost 4.4%, its worst day since April 2025, after midterm election results raised fears that regulation could hurt the AI trade. The Nasdaq Composite fell into correction territory, roughly 11% below the record it set in early October.

A rally on lower oil prices offered some relief at the start of this week. Then inflation data reopened the wound. Consumer prices rose 0.4% in October, the third straight monthly gain of at least that size and a touch above the 0.3% economists had expected. The stock market was still nervous from the prior week’s rout, and it showed. The S&P 500 fell 0.38% to 7,520.93, the Dow lost 0.30% and the Nasdaq Composite slid 0.74% on the news.

Inflation Revives Talk of Fed Rate Hikes

Federal Reserve Governor Christopher Waller said the central bank should raise interest rates in December and consider a half-point increase if inflation worsens. Dallas Fed President Lorie Logan went further, saying at least two more quarter-point hikes are needed to bring prices under control. Three straight monthly gains of 0.4% or more is the kind of streak that keeps rate-hike talk alive.

Traders have taken the message seriously. They now price roughly an 84% chance of a quarter-point December hike, after a week in which both the stock and bond markets swung hard.

Investors tracking how far some AI stocks have fallen can find more names in our ranking of oversold AI stocks that analysts see rebounding by more than half.

Chip Stocks Absorb the Heaviest Selling

Technology shares have taken the brunt of it. Selling in semiconductor stocks reached its most extreme level since 2019 earlier this week, by Yahoo Finance‘s measure, as worries about regulation of the AI trade added to the pressure.

Wednesday brought a rebound. The S&P 500 climbed 1.31% to 7,619.38, the Nasdaq Composite gained 1.60%, and the Dow rose 0.49%. The Nasdaq Composite had slipped into correction territory only days earlier. One day of gains does not erase the damage from the prior week, and the inflation and rate questions behind the selloff are still open. The Dow finished the day at 52,486.49.

Investors comparing cheaper alternatives can start with our roundup of affordable stocks that Wall Street analysts favor.

For now, the Federal Reserve’s December meeting is the date traders are watching, with a hike priced as the likely outcome.

Photo by Arturo Añez on Unsplash

Our Methodology

To compile this list, we reviewed analyst rating downgrades announced on Wednesday, November 11, 2026, from established Wall Street research firms. We have ranked these stocks in ascending order of their average upside potential, based on analysts’ average price target, as of November 11. We also list each stock’s number of hedge fund holders as of Q2 2026, from our database of 1,006 hedge funds.

At Insider Monkey, we are obsessed with what hedge funds do. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 612% since May 2014, beating its benchmark by 375 percentage points (see more details here).

Sell Alert: 10 Stocks Analysts Downgraded on Wednesday

10. Surgery Partners (NASDAQ:SGRY)

Average Upside Potential: -8%

Number of Hedge Fund Holders: 30

Mizuho cut Surgery Partners to Neutral from Outperform on November 11 and raised its price target to $25 from $19, which matches the cash price in the pending buyout. The downgrade follows third-quarter results and a revised offer from HealthSpan Partners. A rival bid of $28 a share arrived, but the board kept backing the amended HealthSpan deal, citing a greater certainty of closing and lower regulatory risk.

Bain Capital owns about 39% of the shares and has agreed to vote for the HealthSpan transaction. Given that support and the board’s recommendation, Mizuho expects shareholders to approve it. The firm also called the deal price a fair multiple of its 2027 adjusted EBITDA estimate for the business, and it updated its estimates through 2028 alongside the call. A special committee unanimously recommended the amended deal.

Surgery Partners runs outpatient surgery centers, and its stock surged when the first offer surfaced. The company has cancelled its forward guidance, so the transaction, expected to close in the first quarter of 2027, now drives the shares. We covered what to expect next after that surge in an earlier piece.

9. Pediatrix Medical Group (NYSE:MD)

Average Upside Potential: -4%

Number of Hedge Fund Holders: 15

Pricing growth at Pediatrix Medical Group slowed to 0.3% in the third quarter from about 4% in each of the two before it. Mizuho took that as a warning. On November 11 the firm cut the stock to Underperform from Neutral and held its price target at $28. It argued that pricing gains have largely plateaued, which limits further upside to earnings per share. Healthcare services stocks have historically traded on volumes, Mizuho added.

Mizuho also pointed to the company’s heavy exposure to the birth rate, a factor management cannot control. With inflation running hot and low birth rates expected, the firm sees little room for a meaningful volume recovery and expects Pediatrix volume growth to lag overall healthcare use.

Pediatrix provides neonatal and maternal-fetal physician services. It still reported adjusted earnings of $0.72 per share for the quarter and raised the floor of its full-year EBITDA outlook. A favorable mix of insurance payers has more than offset weak volumes this year. Our look at how earnings kept growing while patient volumes kept falling covers the setup behind this debate.

Page 1 of 3